CSL News: uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adu - 16th Dec 2022, 11:15pm

annb0t

Top 20
uniQure Inc.

If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people living with hemophilia B

LEXINGTON, Mass. and AMSTERDAM, Dec. 16, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that its partner, global biotechnology leader CSL (ASX: CSL), has received a positive opinion recommending conditional marketing authorization (CMA)...

>>> Read more: uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B
 
Top Bottom